发光探针对健康相关样品中含硼药物德兰佐米的灵敏检测

IF 5.7 2区化学 Q1 CHEMISTRY, ANALYTICAL

Analytica Chimica Acta Pub Date : 2025-05-14 DOI:10.1016/j.aca.2025.344199

Shaozhen Jing , Xiaolei Wu , Xueliang Wang , Daniel Shiu-Hin Chan , Tsun-Yin Li , Chun-Yuen Wong , Chung-Hang Leung , Wanhe Wang , Jing Wang

{"title":"发光探针对健康相关样品中含硼药物德兰佐米的灵敏检测","authors":"Shaozhen Jing , Xiaolei Wu , Xueliang Wang , Daniel Shiu-Hin Chan , Tsun-Yin Li , Chun-Yuen Wong , Chung-Hang Leung , Wanhe Wang , Jing Wang","doi":"10.1016/j.aca.2025.344199","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Boron-containing drugs are widely used in anti-inflammatory, anti-bacterial, anti-tumor and other applications, thus it is important to develop methods for their detection. However, the sensitive detection of delanzomib through its boric acid group remains challenging because of steric hindrance and interference from its own fluorescence.</div></div><div><h3>Results</h3><div>We report an iridium(III) complex containing the 1,2-dione group for the detection of delanzomib for the first time. Complex <strong>1</strong> shows significantly decreased luminescence at 580 nm upon addition of delanzomib in aqueous solution. Complex <strong>1</strong> has good sensitivity and selectivity for delanzomib with a linear relationship in the range of 1–30 μM and a limit of detection (LOD) of 0.628 μM and a limit of quantification (LOQ) of 1 μM. Furthermore, complex <strong>1</strong> is successfully applied for the monitoring of delanzomib in health-related samples.</div></div><div><h3>Significance</h3><div>This study provides a solid basis for the advancement of analytical tools for the monitoring of boron-containing drugs.</div></div>","PeriodicalId":240,"journal":{"name":"Analytica Chimica Acta","volume":"1363 ","pages":"Article 344199"},"PeriodicalIF":5.7000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sensitive detection of boron-containing drug delanzomib by a luminescence probe in health-related samples\",\"authors\":\"Shaozhen Jing , Xiaolei Wu , Xueliang Wang , Daniel Shiu-Hin Chan , Tsun-Yin Li , Chun-Yuen Wong , Chung-Hang Leung , Wanhe Wang , Jing Wang\",\"doi\":\"10.1016/j.aca.2025.344199\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Boron-containing drugs are widely used in anti-inflammatory, anti-bacterial, anti-tumor and other applications, thus it is important to develop methods for their detection. However, the sensitive detection of delanzomib through its boric acid group remains challenging because of steric hindrance and interference from its own fluorescence.</div></div><div><h3>Results</h3><div>We report an iridium(III) complex containing the 1,2-dione group for the detection of delanzomib for the first time. Complex <strong>1</strong> shows significantly decreased luminescence at 580 nm upon addition of delanzomib in aqueous solution. Complex <strong>1</strong> has good sensitivity and selectivity for delanzomib with a linear relationship in the range of 1–30 μM and a limit of detection (LOD) of 0.628 μM and a limit of quantification (LOQ) of 1 μM. Furthermore, complex <strong>1</strong> is successfully applied for the monitoring of delanzomib in health-related samples.</div></div><div><h3>Significance</h3><div>This study provides a solid basis for the advancement of analytical tools for the monitoring of boron-containing drugs.</div></div>\",\"PeriodicalId\":240,\"journal\":{\"name\":\"Analytica Chimica Acta\",\"volume\":\"1363 \",\"pages\":\"Article 344199\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Analytica Chimica Acta\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0003267025005938\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytica Chimica Acta","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003267025005938","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

摘要

含硼药物广泛应用于抗炎、抗菌、抗肿瘤等领域，因此开发含硼药物的检测方法具有重要意义。然而，由于空间位阻和自身荧光的干扰，通过其硼基团对德兰佐米的敏感检测仍然具有挑战性。结果首次报道了一种含有1,2-二酮基团的铱（III）配合物，用于检测德兰佐米。水溶液中加入德兰佐米后，配合物在580 nm处的发光明显降低。配合物1对delanzomib具有良好的选择性和灵敏度，在1 ~ 30 μM范围内呈线性关系，检出限（LOD）为0.628 μM，定量限（LOQ）为1 μM。此外，配合物1已成功应用于健康相关样品中delanzomib的监测。意义本研究为含硼药物监测分析工具的发展提供了坚实的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Sensitive detection of boron-containing drug delanzomib by a luminescence probe in health-related samples

查看原文本刊更多论文

Sensitive detection of boron-containing drug delanzomib by a luminescence probe in health-related samples

Background

Boron-containing drugs are widely used in anti-inflammatory, anti-bacterial, anti-tumor and other applications, thus it is important to develop methods for their detection. However, the sensitive detection of delanzomib through its boric acid group remains challenging because of steric hindrance and interference from its own fluorescence.

Results

We report an iridium(III) complex containing the 1,2-dione group for the detection of delanzomib for the first time. Complex 1 shows significantly decreased luminescence at 580 nm upon addition of delanzomib in aqueous solution. Complex 1 has good sensitivity and selectivity for delanzomib with a linear relationship in the range of 1–30 μM and a limit of detection (LOD) of 0.628 μM and a limit of quantification (LOQ) of 1 μM. Furthermore, complex 1 is successfully applied for the monitoring of delanzomib in health-related samples.

Significance

This study provides a solid basis for the advancement of analytical tools for the monitoring of boron-containing drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Analytica Chimica Acta 化学-分析化学

CiteScore

10.40

自引率

6.50%

发文量

1081

审稿时长

38 days

期刊介绍： Analytica Chimica Acta has an open access mirror journal Analytica Chimica Acta: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Analytica Chimica Acta provides a forum for the rapid publication of original research, and critical, comprehensive reviews dealing with all aspects of fundamental and applied modern analytical chemistry. The journal welcomes the submission of research papers which report studies concerning the development of new and significant analytical methodologies. In determining the suitability of submitted articles for publication, particular scrutiny will be placed on the degree of novelty and impact of the research and the extent to which it adds to the existing body of knowledge in analytical chemistry.